These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 15291353)

  • 41. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
    J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
    Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
    Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A; Colbert A; Lechowicz MJ; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):514-8. PubMed ID: 26297176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
    Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
    Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C
    Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
    Forstpointner R; Unterhalt M; Dreyling M; Böck HP; Repp R; Wandt H; Pott C; Seymour JF; Metzner B; Hänel A; Lehmann T; Hartmann F; Einsele H; Hiddemann W;
    Blood; 2006 Dec; 108(13):4003-8. PubMed ID: 16946304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
    Forstpointner R; Dreyling M; Repp R; Hermann S; Hänel A; Metzner B; Pott C; Hartmann F; Rothmann F; Rohrberg R; Böck HP; Wandt H; Unterhalt M; Hiddemann W;
    Blood; 2004 Nov; 104(10):3064-71. PubMed ID: 15284112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
    Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
    Weide R; Heymanns J; Gores A; Köppler H
    Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
    Zinzani PL; Magagnoli M; Bendandi M; Gherlinzoni F; Orcioni GF; Cellini C; Stefoni V; Pileri SA; Tura S
    Ann Oncol; 2000 Mar; 11(3):363-5. PubMed ID: 10811507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Gherlinzoni F; Merla E; Tura S
    Ann Oncol; 1997 Apr; 8(4):379-83. PubMed ID: 9209669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.